Jingyu Group was established in Fengtai, Beijing in 2020. Relying on the 20-year accumulation of small molecule drug research and development and industrialization of Beijing Gaobo Company, and taking "innovative services and innovative drugs" as the double main line, Jingyu Group has completed the second entrepreneurship and strategic upgrading. It is a comprehensive pharmaceutical technology enterprise integrating molecular building blocks, API (API) and innovative drug self-research. It has been rated as a national high-tech enterprise and Beijing specialized new enterprise, and has completed multiple rounds of financing. Jingyu Group is co-founded by Chairman Wang Fuping and General Manager Gao Ming. The team has both international vision and industrialization ability. There are about 300 employees and 50 R & D personnel (5 doctors). The company focuses on international pharmaceutical companies' patent-expired drugs, provides high value-added, customized and innovative molecular blocks, helps international customers optimize drug synthesis paths, reduce production costs, and enhance product competitiveness. It has established stable cooperation with many well-known pharmaceutical companies around the world. Relationship, products are exported to Europe, America, Japan and South Korea and other markets. In addition, based on the needs of the domestic innovative drug industry, the company provides customized R & D and production of high-end API APIs that meet international standards, covering multiple therapeutic fields such as diabetes, cardiovascular and cerebrovascular, antiviral, and psychotropic. It has an organic synthesis research institute in Beijing., Preparation Research Institute, three GMP production bases in Gansu, with complete delivery capabilities from R & D to industrialization.
